Brexanolone Drug Asset Due Diligence Report 2026

This Brexanolone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

107

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Brexanolone can convert its Small molecule drug profile and GABAA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Brexanolone (query alias: brexanolone)
Modality / target	Small molecule drug; GABAA receptor; GABAA receptor agonists
Highest global status	Phase 3
Originator	Ligand Pharmaceuticals, Inc.
Active developers	SAGE Therapeutics, Inc., Lipocine, Inc.

The MCP disease footprint includes Depression, Postpartum, Perinatal asphyxia, Alcohol Use Disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ACTRN12624000803594	Phase 4	Not yet recruiting	150	Not disclosed
NCT06979544	Phase 3	Completed	90	Change from baseline in HAM-D17 total score compared to placebo
NCT07079761	Phase 2	Recruiting	96	Experiment 1: Extinction retention

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD- Pharmacokinetic Studies

Phase 2; n=11; evaluation: not stated. Reported fields: -; -; -

Temporal Dynamics of Antidepressant Response Following Brexanolone Treatment in Postpartum Depression

Phase 4; n=10; evaluation: Positive. Reported fields: Maternal functioning = 56.0 %

Using Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women During the Perimenopause

Phase 4; n=2; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 0 Participants ; Other (Not Including Serious) Adverse Events = 0 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Brexanolone addresses Depression, Postpartum, Perinatal asphyxia, Alcohol Use Disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 107 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GABAA receptor records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-10	Dong-A ST Licenses Out Epilepsy Drug Cenobamate for Australia, New Zealand	Approved	Financial terms not disclosed
2026-04-21	Tortugas Neuroscience licensed TRTL-107 and TRTL-913 from China’s Hansoh	Phase 2	Financial terms not disclosed
2026-04-08	Assertio signed and closed an agreement to sell all non-Rolvedon assets to Cosette Pharmaceuticals	Approved	US$35.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Analytical method and system for the simultaneous estimation of esketamine and brexanolone”. The milestone feed surfaced a patent-application signal described as “Transmucosal dosage forms of brexanolone”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO